Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Three-year estimates of time-to-event end points

From: Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial

End point 3-Year estimate (%) 95% Confidence interval
Progression-free survival 83.0 (69.8, 98.8)
Overall survival 94.9 (89.5, 100)
Local recurrence-free survival 96.6 (92.1, 100)
Distant metastasis-free survival 89.8 (82.4, 97.9)